Agilent Technologies (A)

• Market cap: $32.4B
• 1 day: -2.84%
• 5 days: -5.85%
• 1 month: -10.03%
• 3 months: -14.82%
• 6 months: -22.45%
• Year to date: -14.82%
• 1 year: -21.92%
• 5 years: 64.92%
• 10 years: 174.61%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Employees: 17,900

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

50% more call options, than puts

Call options by funds: $164M | Put options by funds: $109M

47% more first-time investments, than exits

New positions opened: 132 | Existing positions closed: 90

2% more funds holding

Funds holding: 1,034 [Q3] → 1,055 (+21) [Q4]

1.58% more ownership

Funds ownership: 86.82% [Q3] → 88.4% (+1.58%) [Q4]

6% less repeat investments, than reductions

Existing positions increased: 359 | Existing positions reduced: 380

8% less capital invested

Capital invested by funds: $36.9B [Q3] → $33.9B (-$3.02B) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 12 [Q3] → 8 (-4) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $145 28% upside
• Avg. target: $151 33% upside
• High target: $159 40% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Baird Catherine Schulte 0% 1-year accuracy 0 / 20 met price target	40% upside $159	Outperform Maintained	27 Feb 2025
Barclays Luke Sergott 22% 1-year accuracy 11 / 51 met price target	28% upside $145	Equal-Weight Upgraded	10 Feb 2025
B of A Securities Derik De Bruin 35% 1-year accuracy 7 / 20 met price target	37% upside $156	Neutral Maintained	27 Jan 2025
Bernstein Eve Burstein 43% 1-year accuracy 3 / 7 met price target	28% upside $145	Market Perform Maintained	10 Jan 2025